Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Moo’ved To Split Off Zoetis Business By July 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.

Advertisement

Related Content

Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
Emerging Markets Earnings Roundup: Pfizer (Part 4)
Pfizer Suffers Grim Q3, But Management Points To Future Growth Drivers
Pfizer To Purchase NextWave For ADHD Drug
Deals Of The Week: Merck/Simcere, Pfizer/Hisun, MedImmune/WuXi
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Reading Into Pfizer's Changes: First Steps For New CEO
Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel